Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Malcolm Stoker"'
Autor:
Enrique Ortega, Etta J. Vinik, Aaron I. Vinik, Ladislav Pazdera, Robert Snijder, Nathaniel P. Katz, Malcolm Stoker, Serge Perrot
Publikováno v:
Journal of Current Medical Research and Opinion.
Objective: To determine long-term safety and effectiveness of repeat treatments with a high concentration capsaicin patch. Methods: In this 52-week, open-label, randomized controlled study, patients with painful diabetic peripheral neuropathy (PDPN)
Autor:
Florence Paillard, Nathaniel P. Katz, Malcolm Stoker, Barry Turnbull, Jeremiah J. Trudeau, Joy Mou
Publikováno v:
The Clinical Journal of Pain. 31:859-866
Qutenza is a high-dose capsaicin patch used to relieve neuropathic pain from postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN). In clinical studies, some patients had a dramatic response to the capsaicin patch. Our objective was to
Autor:
Stephen K. Long, Malcolm Stoker, Cathelijne Alleman, Kirsten Y. Westerhout, C. Chambers, Floortje van Nooten, Marja Hensen
Publikováno v:
Diabetes Research and Clinical Practice. 109:215-225
Aims Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes mellitus. A systematic literature review was conducted to provide an overview of published literature in the last 10-years on the epidemiology, humanistic burden
Autor:
Jeremiah J. Trudeau, Barry Turnbull, Florence Paillard, Joy Mou, Malcolm Stoker, Nathaniel P. Katz
Publikováno v:
Pain. 154:1632-1639
Qutenza® is a capsaicin patch used to treat peripheral neuropathic pain, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN). The Qutenza Clinical Trials Database has been assembled to more fully ch
Autor:
Christian Maihöfner, Nadine Attal, Graeme Moyle, Etienne Ernault, Turo Nurmikko, Malcolm Stoker, Marie-Louise Navez, Rafael Gálvez
Journal Article; OBJECTIVES To investigate long-term safety and tolerability of capsaicin 8% patch repeat treatment in non-diabetic patients with peripheral neuropathic pain (NP). METHODS Prospective, open-label, observational study in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1227068f4aa8f091b422b31054223bb0
https://hdl.handle.net/10668/2600
https://hdl.handle.net/10668/2600
Autor:
Aaron I. Vinik, Enrique Ortega, Nathaniel P. Katz, Robert Snijder, Malcolm Stoker, Serge Perrot, Stephen K. Long, Ladislav Pazdera, Etta J. Vinik, Hélène Jacobs, Marjolijne van der Stoep
Publikováno v:
BMC Neurology
Background This 52-week study evaluated the long-term safety and tolerability of capsaicin 8% w/w (179 mg) patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy (PDPN). Methods Phase 3, multinat
Publikováno v:
Clinical Therapeutics. 39:787-803.e18
Purpose A network meta-analysis (NMA) was performed, aiming to assess the relative efficacy and tolerability of the capsaicin 179-mg (8% weight for weight) cutaneous patch (capsaicin 8% patch) compared with oral, centrally acting agents (ie, pregabal
Autor:
Hélène Jacobs, Stephen K. Long, Etta J. Vinik, Serge Perrot, Nathaniel P. Katz, Enrique Ortega, Malcolm Stoker, Robert Snijder, Aaron I. Vinik, Marjolijne van der Stoep, Ladislav Pazdera
Publikováno v:
Endocrine Practice. 21:41-42
Autor:
C. Chambers, Malcolm Stoker, Stephen K. Long, Cathelijne Alleman, K.Y. Westerhout, Marja Hensen, F.E. van Nooten
Publikováno v:
Value in Health. 16(7)
Autor:
Nathaniel P. Katz, Jeremiah J. Trudeau, Florence Paillard, Malcolm Stoker, Joy Mou, Barry Turnbull
Publikováno v:
The Clinical journal of pain. 30(4)
Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN).We conducted a meta-analysis of Qutenza studies to describe clinical